CY1105766T1 - Χρηση συνθεσεων που εμπepιεχουν ενα οιστρογονικο συστατικο για τη θepαπευτικη αγωγη και προληψη των μυοσκελετικων πονων - Google Patents
Χρηση συνθεσεων που εμπepιεχουν ενα οιστρογονικο συστατικο για τη θepαπευτικη αγωγη και προληψη των μυοσκελετικων πονωνInfo
- Publication number
- CY1105766T1 CY1105766T1 CY20061101608T CY061101608T CY1105766T1 CY 1105766 T1 CY1105766 T1 CY 1105766T1 CY 20061101608 T CY20061101608 T CY 20061101608T CY 061101608 T CY061101608 T CY 061101608T CY 1105766 T1 CY1105766 T1 CY 1105766T1
- Authority
- CY
- Cyprus
- Prior art keywords
- estrogenic component
- prevention
- group
- musculoskeletal pain
- inhibitors
- Prior art date
Links
- 230000001076 estrogenic effect Effects 0.000 title abstract 3
- 206010028391 Musculoskeletal Pain Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 239000003112 inhibitor Substances 0.000 abstract 2
- 239000002243 precursor Chemical class 0.000 abstract 2
- 102100037426 17-beta-hydroxysteroid dehydrogenase type 1 Human genes 0.000 abstract 1
- 101710147298 17-beta-hydroxysteroid dehydrogenase type 1 Proteins 0.000 abstract 1
- 101710174215 Estradiol 17-beta-dehydrogenase 1 Proteins 0.000 abstract 1
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical class C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 229940046836 anti-estrogen Drugs 0.000 abstract 1
- 230000001833 anti-estrogenic effect Effects 0.000 abstract 1
- 239000003886 aromatase inhibitor Substances 0.000 abstract 1
- 229940046844 aromatase inhibitors Drugs 0.000 abstract 1
- 125000004432 carbon atom Chemical class C* 0.000 abstract 1
- 239000000262 estrogen Substances 0.000 abstract 1
- 229940011871 estrogen Drugs 0.000 abstract 1
- 239000000328 estrogen antagonist Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000000583 progesterone congener Substances 0.000 abstract 1
- 229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 abstract 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Η παρούσα ανακάλυψη αφορά σε μία μέθοδο για τη θεραπευτική αγωγή ή την πρόληψη των μυοσκελετικών πόνων σε θηλαστικά τα οποία λαμβάνουν έναν καταστολέα οιστρογόνων που έχει επιλεγεί από την ομάδα που περιλαμβάνει τους αναστολείς της αρωματάσης, τα GnRH ανάλογα, τους αναστολείς της κυκλο-οξυ-γενάσης 2 (COX-2), τους αναστολείς της 17β-υδροξυστεροειδούς αφυδρογενάσης τύπου 1, τα προγεσταγόνα, τα αντι-οιστρογόνα και συνδυασμούς τους, η αναφερόμενη μέθοδος περιλαμβάνει τη χορήγηση μίας αποτελεσματικής ποσότητας ενός οιστρογονικού συστατικού, όπου το οιστρογονικό συστατικό επιλέγεται από την ομάδα που αποτελείται από: ενώσεις που αναπαριστώνται από τον ακόλουθο τύπο (1) όπου τα R1 R2, R3, R4 είναι ανεξαρτήτως ένα άτομο υδρογόνου, μία ομάδα υδροξυλίου ή μία ομάδα αλκοξυλίου με 1-5 άτομα άνθρακα· πρόδρομες ενώσεις ικανές να ελευθερώσουν μία ένωση που ακολουθεί τον παραπάνω τύπο όταν χρησιμοποιούνται στην παρούσα μέθοδο και μίγματα μίας ή περισσότερων από τις προαναφερόμενες ενώσεις και/ή προδρόμων ενώσεων.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03076555 | 2003-05-22 | ||
EP04734005A EP1624878B1 (en) | 2003-05-22 | 2004-05-19 | Use of compositions comprising an estrogenic component for the treatment and prevention of musculoskeletal pain |
PCT/NL2004/000354 WO2004103377A1 (en) | 2003-05-22 | 2004-05-19 | Use of compositions comprising an estrogenic component for the treatment and prevention of musculoskeletal pain |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1105766T1 true CY1105766T1 (el) | 2011-02-02 |
Family
ID=33462160
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20061101608T CY1105766T1 (el) | 2003-05-22 | 2006-11-08 | Χρηση συνθεσεων που εμπepιεχουν ενα οιστρογονικο συστατικο για τη θepαπευτικη αγωγη και προληψη των μυοσκελετικων πονων |
Country Status (13)
Country | Link |
---|---|
US (1) | US20060276414A1 (el) |
EP (1) | EP1624878B1 (el) |
CN (1) | CN100431545C (el) |
AT (1) | ATE340580T1 (el) |
CA (1) | CA2526338C (el) |
CY (1) | CY1105766T1 (el) |
DE (1) | DE602004002591T9 (el) |
DK (1) | DK1624878T3 (el) |
ES (1) | ES2274456T3 (el) |
PL (1) | PL1624878T3 (el) |
PT (1) | PT1624878E (el) |
SI (1) | SI1624878T1 (el) |
WO (1) | WO2004103377A1 (el) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2299730T3 (es) * | 2002-07-12 | 2008-06-01 | Pantarhei Bioscience B.V. | Composicion farmaceutica que comprende derivados de estetrol para el uso en la terapia del cancer. |
US20080287408A1 (en) * | 2007-05-14 | 2008-11-20 | Drugtech Corporation | Endometriosis treatment |
KR20100068287A (ko) * | 2007-09-17 | 2010-06-22 | 쁘레글렘 에스.아. | 폐경기 전 여성의 에스트로겐 의존성 질환의 치료 |
DK2714712T3 (en) | 2011-06-01 | 2016-12-05 | Estetra Sprl | A process for the preparation of intermediates estetrol |
HUE029252T2 (en) | 2011-06-01 | 2017-02-28 | Estetra Sprl | Process for the preparation of intermediates of estetrol |
EP2383279A1 (en) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Process for the preparation of estetrol |
EP3936133A1 (en) | 2011-11-23 | 2022-01-12 | TherapeuticsMD, Inc. | Natural combination hormone replacement formulations and therapies |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
CA2947767A1 (en) | 2014-05-22 | 2015-11-26 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
RS61812B1 (sr) * | 2015-06-18 | 2021-06-30 | Estetra Sprl | Oralno-disperzibilna tableta koja sadrži estetriol |
AU2016280863B2 (en) | 2015-06-18 | 2021-04-01 | Estetra Srl | Orodispersible dosage unit containing an estetrol component |
KR102662025B1 (ko) | 2015-06-18 | 2024-05-02 | 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 | 에스테트롤 성분을 함유하는 구강분해성 투여 단위 |
MD3310346T2 (ro) | 2015-06-18 | 2021-06-30 | Estetra Sprl | Comprimată orodispersabilă ce conține estetrol |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
BR112018070199A2 (pt) | 2016-04-01 | 2019-01-29 | Therapeuticsmd Inc | composição farmacêutica de hormônio esteroide |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
CA3178291A1 (en) | 2016-08-05 | 2018-04-12 | Estetra Srl | Method for the management of dysmenorrhea and menstrual pain |
TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
JOP20200260A1 (ar) | 2018-04-19 | 2019-10-19 | Estetra Sprl | مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث |
EP3787632B1 (en) | 2018-05-02 | 2022-05-25 | Estetra SPRL | Treatment regimen for the treatment of advanced oestrogen receptor positive breast cancer |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2834712A (en) * | 1953-05-27 | 1958-05-13 | American Home Prod | Urinary estrogen compositions and methods for preparing them |
US2753290A (en) * | 1953-08-06 | 1956-07-03 | Olin Mathieson | Microbiological production of 7-and 15-hydroxy-progesterones |
US3440320A (en) * | 1964-06-18 | 1969-04-22 | Mortimer D Sackler | Chelated suppository and method of using same |
US3487152A (en) * | 1967-02-07 | 1969-12-30 | Hoffmann La Roche | Tablets containing 7 - chloro - 2 - methylamino - 5 - phenyl - 3h - 1,4 - benzodiazepine-4-oxide and conjugated estrogenic substances |
US3608075A (en) * | 1969-07-28 | 1971-09-21 | American Home Prod | Compositions and methods of treating the menopausal syndrome |
YU243975A (en) * | 1974-10-14 | 1982-06-30 | Schering Ag | Process for obtaining 7-hydroxyestradiols |
FR2377419A1 (fr) * | 1977-01-13 | 1978-08-11 | Roussel Uclaf | Nouveaux derives steroides 11b-substitues 1,3,5 (10) trieniques, leur procede de preparation et leur application comme medicament |
US4937238A (en) * | 1986-03-04 | 1990-06-26 | The Board Of Regents Of The University Of Nebraska | Prevention of mammary carcinoma |
US4762717A (en) * | 1986-03-21 | 1988-08-09 | The General Hospital Corporation | Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use as a contraceptive |
US5340586A (en) * | 1991-04-12 | 1994-08-23 | University Of Southern California | Methods and formulations for use in treating oophorectomized women |
US5340585A (en) * | 1991-04-12 | 1994-08-23 | University Of Southern California | Method and formulations for use in treating benign gynecological disorders |
US5211952A (en) * | 1991-04-12 | 1993-05-18 | University Of Southern California | Contraceptive methods and formulations for use therein |
US5270172A (en) * | 1991-04-26 | 1993-12-14 | Dekk-Tek, Inc. | Method to predict tumor response to therapy |
US5468736A (en) * | 1993-02-25 | 1995-11-21 | The Medical College Of Hampton Road | Hormone replacement therapy |
US5811416A (en) * | 1994-06-06 | 1998-09-22 | Board Of Regents The University Of Texas System | Endothelin antagonist and/or endothelin synthase inhibitor in combination with a progestin, an estrogen, a cyclooxygenase inhibitor, or a nitric acid donor or substrate |
US6613757B1 (en) * | 1994-09-22 | 2003-09-02 | Board Of Regents, The University Of Texas System | Combination of prostacyclin with an estrogen or progestin for the prevention and treatment of atherosclerotic vascular disease including preeclampsia and for the treatment of hypertension, and for hormone replacement therapy |
US5672609A (en) * | 1996-07-18 | 1997-09-30 | Eli Lilly And Company | Pyridine compounds, intermediates compositions and methods of use |
US6170058B1 (en) * | 1997-12-23 | 2001-01-02 | Arcot Systems, Inc. | Method and apparatus for cryptographically camouflaged cryptographic key storage, certification and use |
US20010056068A1 (en) * | 1998-03-04 | 2001-12-27 | Kristof Chwalisz | Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives |
US6291456B1 (en) * | 1998-12-30 | 2001-09-18 | Signal Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
US6117446A (en) * | 1999-01-26 | 2000-09-12 | Place; Virgil A. | Drug dosage unit for buccal administration of steroidal active agents |
GB0005257D0 (en) * | 2000-03-03 | 2000-04-26 | Pharmacia & Upjohn Spa | Breast cancer hormonal therapy |
RU2180570C1 (ru) * | 2000-09-25 | 2002-03-20 | Писаревский Юрий Леонидович | Способ лечения болевого синдрома при дисфункциях височно-нижнечелюстного сустава у женщин |
US6790979B2 (en) * | 2002-04-17 | 2004-09-14 | University Of North Carolina At Chapel Hill | Curcumin analogues and uses thereof |
-
2004
- 2004-05-19 SI SI200430120T patent/SI1624878T1/sl unknown
- 2004-05-19 US US10/557,549 patent/US20060276414A1/en not_active Abandoned
- 2004-05-19 CN CNB2004800177699A patent/CN100431545C/zh not_active Expired - Lifetime
- 2004-05-19 WO PCT/NL2004/000354 patent/WO2004103377A1/en active IP Right Grant
- 2004-05-19 ES ES04734005T patent/ES2274456T3/es not_active Expired - Lifetime
- 2004-05-19 EP EP04734005A patent/EP1624878B1/en not_active Expired - Lifetime
- 2004-05-19 AT AT04734005T patent/ATE340580T1/de active
- 2004-05-19 DK DK04734005T patent/DK1624878T3/da active
- 2004-05-19 CA CA2526338A patent/CA2526338C/en not_active Expired - Lifetime
- 2004-05-19 PL PL04734005T patent/PL1624878T3/pl unknown
- 2004-05-19 PT PT04734005T patent/PT1624878E/pt unknown
- 2004-05-19 DE DE602004002591T patent/DE602004002591T9/de active Active
-
2006
- 2006-11-08 CY CY20061101608T patent/CY1105766T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
PL1624878T3 (pl) | 2007-01-31 |
CA2526338C (en) | 2012-09-25 |
WO2004103377A1 (en) | 2004-12-02 |
EP1624878B1 (en) | 2006-09-27 |
DE602004002591D1 (de) | 2006-11-09 |
PT1624878E (pt) | 2007-01-31 |
SI1624878T1 (sl) | 2007-02-28 |
DE602004002591T9 (de) | 2008-01-03 |
ES2274456T3 (es) | 2007-05-16 |
CN100431545C (zh) | 2008-11-12 |
EP1624878A1 (en) | 2006-02-15 |
CA2526338A1 (en) | 2004-12-02 |
ATE340580T1 (de) | 2006-10-15 |
CN1816340A (zh) | 2006-08-09 |
US20060276414A1 (en) | 2006-12-07 |
DE602004002591T2 (de) | 2007-08-09 |
DK1624878T3 (da) | 2007-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1105766T1 (el) | Χρηση συνθεσεων που εμπepιεχουν ενα οιστρογονικο συστατικο για τη θepαπευτικη αγωγη και προληψη των μυοσκελετικων πονων | |
SV2006002103A (es) | Compuestos de aril- o heteroarilamida ortosustituidos ref. pc32242a | |
CY1105957T1 (el) | Χρηση οιστρογονων ενωσεων σε συνδυασμο με ενωσεις προγεστογονου (progestogen) σε θepαπεια ορμονικης αντικαταστασης | |
SV2005002102A (es) | Compuestos de metil-aril o heteroaril-amida sustituida ref. pc32241a | |
PA8610801A1 (es) | Compuestos de aril o heteroaril amida | |
UY28674A1 (es) | Inhibidores heterociclil amino de 11-beta-hidroxiesteroide deshidrogenasa tipo 1 | |
SG155967A1 (en) | Hcv ns3-ns4a protease inhibition | |
NO20062617L (no) | Anvendelse av glukosidase inhibitorer for terapi av mucovisidose | |
BR0014541A (pt) | Compostos quìmicos | |
ATE256681T1 (de) | N-heterozyklische derivate als nos inhibitoren | |
PL369108A1 (en) | 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | |
ATE252097T1 (de) | N-heterocyclische derivate als nos inhibitoren | |
IL184116A0 (en) | Use of thiazolidinone derivatives as antiangiogenic agents | |
HK1081194A1 (en) | 6-amino-1h-indazole compounds as phosphodiesterase4 inhibitors, pharmaceutical compositions compris ing the same, and use thereof | |
AR012878A1 (es) | Un compuesto derivado de 5'-desoxicitidina, su uso, un proceso para fabricarlo, composiciones farmaceuticas que lo comprende, y un kit que comprende dicha composicion. | |
DK1511472T3 (da) | Anvendelige forbindelser til behandling af Anthrax og hæmning af letalfaktor | |
BRPI0416289A (pt) | 4-anilino-3-quinolinacarbonitrilas para o tratamento de leucemia mielógeno crÈnica (cml) | |
HUP0402341A2 (hu) | Szubsztituált tiazol-2-ilaminokat tartalmazó készítmények rák kezelésére | |
DE602004018811D1 (de) | Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren | |
DE60324401D1 (de) | Iodierte triglycerid-derivate | |
IL150100A0 (en) | Pharmaceutical compositions containing fused cyclic compounds | |
BR0212454A (pt) | Composto, composição farmacêutica, métodos para o tratamento ou prevenção de distúrbios fisiológicos associados com um excesso de taquicininas e de dor ou inflamação, enxaqueca, êmese, neuralgia pós-terpética, depressão ou ansiedade, e, uso de um composto | |
HUP0401189A2 (hu) | Új mandulasavszármazékok és felhasználásuk trombin inhibitorokként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
DE69527789D1 (de) | Mittel zur behandlung von kachexie die im zusammenhang mit tumoren steht | |
TW200621740A (en) | Compound for treating hepatitis B and composition thereof |